ArticleFrontiers in oncology2026
Associations between pretreatment composite inflammatory indices and pathological response to neoadjuvant therapy in breast cancer: a retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pretreatment inflammatory indices may reflect the host immune-inflammatory status in breast cancer. Evidence comparing multiple composite indices across pathological response endpoints after neoadjuvant therapy remains limited. This study evaluated the associations between pretreatment composite inflammatory indices and pathological response in breast cancer. Methods: This retrospective study included 280 patients with breast cancer who underwent neoadjuvant therapy followed by surgery. Baseline neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and pan-immune-inflammation value were calculated from pretreatment blood tests. The primary endpoint was pathological complete response, defined as ypT0/is ypN0. Miller-Payne grades 4-5 were defined as favorable pathological response. Logistic regression and receiver operating characteristic analyses were performed. Results: A total of 115 patients achieved pathological complete response. Patients with pathological complete response had lower neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value than those without pathological complete response. These indices remained inversely associated with pathological complete response after multivariable adjustment. For favorable Miller-Payne response, lower systemic immune-inflammation index and pan-immune-inflammation value and higher lymphocyte-to-monocyte ratio were associated with better response. Systemic immune-inflammation index had the numerically highest area under the curve, with values of 0.673 for pathological complete response and 0.666 for favorable Miller-Payne response, although its discriminatory ability remained modest. Conclusion: Baseline composite inflammatory indices were associated with pathological response to neoadjuvant therapy in breast cancer, but their discriminatory ability was modest. These indices may be more suitable as supplementary markers than as standalone predictors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.